- Home
- KPTI vs ELUT Comparison
KPTI vs ELUT Comparison
Compare KPTI & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | ELUT |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 42.5M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KPTI | ELUT |
|---|---|---|
| Price | $1.58 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $16.00 | $6.00 |
| AVG Volume (30 Days) | ★ 1.3M | 50.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.36 | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.24 | $0.50 |
| 52 Week High | $10.99 | $1.39 |
Technical Indicators
Market Signals| Indicator | KPTI | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 36.08 |
| Support Level | N/A | $0.51 |
| Resistance Level | $2.16 | $1.03 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 40.00 | 1.39 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.